pharmaphorum

MARCH 3, 2022

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with the condition. The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 da

Labelling 98

Labelling Hospitals 98

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA.

Immunization 52

Immunization Hospitals FDA 52

pharmaphorum

MARCH 3, 2022

DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Under the terms of the five-year deal, Sanofi digital health apps will be integrated into Dario’s platform and Sanofi’s sales muscle will be deployed to market the combined offering.

91

91

Outsourcing Pharma

MARCH 3, 2022

The drug discovery firm will work with the Dean Felsher Laboratory, using the companyâs transomics platform to discover therapies for untreatable cancers.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 3, 2022

Digital transformation is taking root in every major industry, and healthcare and life sciences are no exception. In fact, digital technology may prove to be more transformative in the healthcare sphere than in other industries as it forces us to rethink core concepts like episodes of care and small molecules in favour of emerging models and tools like ongoing virtual care, digital medicines and therapeutics.

59

59

Outsourcing Pharma

MARCH 3, 2022

This monthâs announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.

52

52

Pharma Times

MARCH 3, 2022

The phase 3 MELODY study reveals that nirsevimab vaccine reduces lower respiratory tract infections

Vaccines 49

Vaccines 49

pharmaphorum

MARCH 3, 2022

The UK biopharma industry has welcomed a new tranche of funding from the government aimed at bolstering manufacturing of medicinal products and developing the national health data infrastructure. The investment package includes £200 million ($268 million) to enable researchers to better access NHS data through what the government calls Trusted Research Environments and digital clinical trial services.

Packaging 52

Packaging Patient Care 52

Pharma Times

MARCH 3, 2022

NICE document recommends Amgen’s Lumykras (sotorasib) to treat non-small-cell lung cancer

Documentation 48

Documentation 48

pharmaphorum

MARCH 3, 2022

Global health innovation and technology leader, Healthware, has announced the acquisition of Argon Global Healthcare, one of the largest international networks of independent healthcare agencies. Milan and London, 2 March 2022 – Healthware Group , a global health innovation and technology leader, providing advisory, agency and digital health services, has announced its acquisition of Argon Global Healthcare , one of the largest international networks of independent healthcare agencies.

Communication 52

Communication 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

MARCH 3, 2022

One year ago, a UK-wide vision for the country’s future research landscape promised streamlined processes, and a patient-centred, competitive environment. But how far have we come in achieving those aims? And what’s next on the system’s agenda? From Brexit and COVID-19 to the wholescale shift in the way research is designed, conducted, and reported, the UK’s clinical trials sector has faced a raft of challenges in recent years.

91

91

pharmaphorum

MARCH 3, 2022

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant women, putting the company in pole position to bring a shot to market that will protect infants from the life-threatening infection. The news comes just days after GlaxoSmithKline called a halt to enrolment and vaccination in three trials of its RSV shot in pregnant women while it investigates a safety signal.

Vaccines 52

Vaccines FDA 52

pharmaphorum

MARCH 3, 2022

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. First launched in 2018 to to tackle shortages in lifesaving medicines and improve the affordability of drugs, Civica has now teamed up with a consortium of US health systems and other stakeholders, including Kaiser Permanente, Intermountain Healthcare, and the Mayo Clinic, on the insulin project.

Mayo Clinic 52

Mayo Clinic Insurance FDA 52